BrainsWay Secures $20 Million in Funding to Advance Groundbreaking Neurostimulation Treatments

In a landmark funding milestone, BrainsWay, a pioneering force in the domain of noninvasive neurostimulation treatments, has successfully raised $20 million to enhance its groundbreaking work in mental health therapies. Known globally for its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform, BrainsWay is at the forefront of revolutionizing neurotherapy, aimed at transforming the lives of individuals suffering from mental health disorders. This strategic funding will empower the company to expand its extensive portfolio of clinically proven treatments, which currently includes FDA-cleared interventions for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. Pivotal studies supporting their innovative approaches underline their commitment to superior science, reinforcing the efficacy of Deep TMS in reducing symptoms of anxiety often associated with major depressive episodes. With several additional clinical trials underway targeting various psychiatric, neurological, and addiction disorders, BrainsWay is not only enhancing its therapeutic framework but also increasing global awareness and access to these life-changing therapies. Founded in 2003, and operating from offices in Burlington, MA, and Jerusalem, Israel, BrainsWay's mission is resolutely focused on transforming mental health care through advanced science and innovation. As they leverage this significant funding, the company is poised to further its impact on mental health treatment, driving the conversation on neurotherapeutics for a better tomorrow. For further updates on BrainsWay's initiatives and advancements, please visit www.brainsway.com.